Carbohydrate deficient glycoprotein syndrome type IIh is a very rare inherited metabolic disease. It belongs to a group of diseases called congenital disorders of glycosylation (CDG). In this disease, the body has trouble adding sugar chains correctly to many proteins. These sugar chains are called glycans, and they are added inside a cell part named the Golgi apparatus.
Doctors now usually call this condition “COG8-congenital disorder of glycosylation” or “COG8-CDG,” because changes (mutations) in a gene called COG8 cause the disease. The COG8 gene gives instructions to make one part of the conserved oligomeric Golgi (COG) complex, which is a group of proteins that helps move and process other proteins inside the Golgi. When COG8 does not work, many glycoproteins in the body are under-glycosylated (they have missing sugar chains) and cannot do their jobs well.
Carbohydrate-deficient glycoprotein syndrome type IIh, also called COG8-congenital disorder of glycosylation (COG8-CDG or CDG type IIh), is an ultra-rare inherited metabolic disease that affects how sugar chains (glycans) are attached to proteins inside the Golgi apparatus of cells. In this condition, harmful changes (mutations) in the COG8 gene damage part of the “conserved oligomeric Golgi” (COG) complex, a group of proteins that controls traffic inside the Golgi. Because the Golgi can no longer correctly process and ship many glycoproteins, important organs such as the brain, muscles, liver, gut and endocrine system do not work properly. Children who have COG8-CDG often show severe developmental delay, very poor muscle tone, feeding problems, failure to gain weight (failure to thrive), seizures, and an intolerance to wheat and dairy products. Laboratory tests show abnormal glycosylation patterns on blood proteins, and genetic testing confirms a COG8 mutation. There is currently no cure, and treatment is mainly supportive and focused on managing symptoms and preventing complications.
Because this disease is extremely rare, almost all treatment information comes from small case reports and general congenital disorder of glycosylation (CDG) guidelines. Most therapies used for COG8-CDG are adapted from broader CDG experience and from standard care for developmental disabilities, epilepsy, feeding problems, and multisystem chronic illness in children. This means that every child needs a personalised care plan designed by a metabolic specialist, neurologist, nutritionist and rehabilitation team, and families should understand that evidence is limited and recommendations can change as new research appears.
This condition is autosomal recessive. That means a child becomes sick only when they receive one changed COG8 gene from each parent. Both parents are usually healthy carriers and do not show symptoms. The disease often starts in early infancy or childhood and mainly affects the brain, muscles, growth, and sometimes other organs. Only a small number of patients have been reported worldwide, so doctors are still learning about the full range of symptoms.
Other names and classification
Carbohydrate deficient glycoprotein syndrome type IIh has many other names in medical databases. Different doctors or labs may use different terms, but they all refer to the same disease. Common synonyms include:
-
CDG IIh
-
CDG2H or CDG-IIh
-
COG8-CDG
-
COG8-congenital disorder of glycosylation
-
Congenital disorder of glycosylation type 2h
-
Congenital disorder of glycosylation type IIh
Databases such as the Genetic and Rare Diseases Information Center at the National Institutes of Health and Disease Ontology list these names, so you may see any of them in reports or scientific papers.
In classification systems, this disease is placed under “congenital disorders of glycosylation, type II,” and also under “autosomal recessive rare neurologic and metabolic diseases.” It is usually coded as a disorder of glycoprotein metabolism in the ICD-10 chapter E77.
Types or ways doctors describe this condition
Doctors do not describe many different sub-types inside CDG type IIh itself. Instead, they group or describe it in a few useful ways:
-
By gene name – “COG8-CDG” or “COG8-congenital disorder of glycosylation” highlights that changes are in the COG8 gene.
-
By CDG class – “CDG type IIh” means it is in the type II subgroup, which includes disorders where the basic building of sugar chains starts, but later trimming and finishing in the Golgi is faulty.
-
By main organ involvement – some reports focus on it as a “neurodevelopmental CDG,” because the brain, movement, and development are strongly affected.
-
By severity – case reports talk about “severe” or “milder” forms, based on how strong the disability, seizures, and growth problems are, though there is no official severity scale yet.
-
By age at presentation – some patients show signs before birth (antenatal) while others are noticed during infancy or early childhood, so doctors may call it “antenatal-onset” or “childhood-onset” COG8-CDG in articles.
Causes and disease mechanism
How the cause works in simple words
The root cause is a harmful change (mutation) in both copies of the COG8 gene. This gene is needed to build a part of the COG complex inside the Golgi apparatus. When this part is missing or not working, the Golgi cannot finish sugar chains on proteins properly. These half-finished proteins are then sent out around the body and cannot work as they should, especially in the brain and muscles.
Below are 20 simple points that explain the cause and mechanism in more detail:
-
COG8 gene mutations – The basic cause is a mutation in the COG8 gene on chromosome 16q22.1. These mutations can be nonsense, missense, or splice-site changes and lead to a faulty or missing COG8 protein.
-
Autosomal recessive inheritance – A child must inherit one faulty COG8 gene from each parent. Parents are usually healthy carriers with one normal and one changed copy of the gene.
-
Disrupted COG complex – COG8 protein normally helps connect two parts of the COG complex. Without COG8, the complex does not assemble correctly, so Golgi trafficking and protein recycling are disturbed.
-
Faulty Golgi function – The Golgi works like a “post-office” that modifies and sorts proteins. When the COG complex fails, the Golgi cannot move enzymes and cargo to the right place, leading to wide-spread glycosylation problems.
-
Abnormal N-glycosylation – Studies show that serum transferrin and other N-glycoproteins have abnormal patterns, with missing terminal sialic acid residues and under-glycosylated forms.
-
Abnormal O-glycosylation – In some patients, O-glycan processing in fibroblasts is also disturbed, so both main sugar pathways on proteins can be affected.
-
Under-glycosylated serum proteins – Many proteins in blood that normally carry sugar chains are partly empty. This can disturb blood clotting, hormone transport, and many signaling pathways.
-
Brain vulnerability – The developing brain depends heavily on correctly glycosylated proteins for cell communication, migration, and synapse function. When these are faulty, severe developmental delay and seizures can occur.
-
Muscle and tone problems – Glycoproteins are also important in muscle and nerve connections. Their poor glycosylation contributes to hypotonia (low muscle tone), weakness, and later contractures.
-
Growth failure – Glycosylation defects can affect hormones such as growth factors and appetite control, which may help explain failure to thrive and low weight in many patients.
-
Intestinal intolerance – The first reported COG8-CDG patient had intolerance to wheat and dairy products. This may be due to disturbed gut enzymes or transporters that are also glycoproteins.
-
Possible liver involvement – Some CDG disorders, including COG-related types, can affect liver function tests and protein production, because many liver proteins are glycoproteins.
-
Endocrine and metabolic stress – Broad CDG reviews show that glycosylation problems can disturb hormone receptors and metabolic enzymes, adding extra stress on already weak systems.
-
Oxidative and cellular stress – Faulty trafficking in the Golgi can cause protein mis-folding and accumulation, which may lead to cellular stress responses and possibly cell damage or death.
-
Brain imaging changes – Abnormal glycosylation may lead over time to brain atrophy or cerebellar changes on MRI, showing that brain structure itself is affected by the underlying protein defects.
-
Variable expressivity – Different mutations in COG8 can cause different levels of residual protein activity. This may explain why some patients are extremely severely affected and others survive longer with a somewhat milder course.
-
Very low number of cases – Only a handful of patients with confirmed COG8-CDG have been reported. With so few cases, many possible clinical and molecular mechanisms are still unknown.
-
No environmental “cause” – There is no evidence that food, infection, pregnancy events, or toxins “cause” this disease. They may make symptoms worse, but the root cause remains the inherited gene mutation.
-
Carrier status in families – Siblings of an affected child may be carriers or, more rarely, also affected. Carrier testing and genetic counseling can help families understand their personal recurrence risk.
-
Part of the larger CDG spectrum – Because many different genes can cause CDG, some general features (like hypotonia and developmental delay) arise from shared glycosylation problems, while other features are more specific to COG8 mutations.
Symptoms and signs
Not every patient has all of these symptoms, but the following 15 features are commonly reported or expected in COG8-CDG and related CDG conditions.
-
Severe developmental delay – Many children are late in sitting, standing, walking, and speaking. They may never reach some milestones or reach them very late compared with other children.
-
Intellectual disability – Because the brain is affected, there is often difficulty with learning, understanding, and problem solving. This can be mild to very severe.
-
Hypotonia (low muscle tone) – Babies may feel “floppy” when held and have trouble lifting their head or moving against gravity. Low tone often remains a major feature throughout life.
-
Seizures – Many patients have seizures. Some can be frequent or hard to control and may include different types, such as generalized seizures or status epilepticus in severe cases.
-
Failure to thrive – Poor weight gain, small size for age, and feeding difficulties are common. Children may need special feeding support or tube feeding.
-
Microcephaly (small head) – Some children have a head size that is smaller than expected for age and sex. This often reflects abnormal brain growth.
-
Abnormal eye movements or strabismus – Eyes may not line up correctly (squint, exotropia) or may move in an unusual way. This can affect vision and tracking.
-
Ataxia and poor coordination – Children can have shaky, unsteady movements or trouble with balance and coordination. This is often linked to cerebellar involvement.
-
Speech problems – Speech may be slow, unclear, or very limited. Some children may only say a few words or communicate mainly with gestures and facial expression.
-
Feeding and swallowing difficulties – Babies may have trouble sucking or swallowing safely. They may cough or choke during feeds or have reflux.
-
Muscle weakness and contractures – Over time, some patients develop stiffness or fixed positions in joints (contractures) along with muscle wasting, especially in the legs.
-
Abnormal skin findings – Dry skin or small rough bumps called keratosis pilaris were noted in at least one reported case, showing that the skin can also be affected.
-
Possible liver or clotting issues – In some CDG disorders, liver tests may be abnormal and clotting may be disturbed. Similar problems may occur in COG8-CDG, although data are limited.
-
Behavior and sleep problems – Like many neurodevelopmental disorders, children may have irritability, poor sleep, or unusual behavior linked to discomfort, seizures, or communication difficulty.
-
Shortened life span in severe cases – Some forms of CDG, including COG-related forms, have been associated with serious complications and early death, especially in very severe cases. However, the exact life expectancy for COG8-CDG is still not well known because so few patients are described.
Diagnostic tests
Doctors do not rely on one single test. They combine careful clinical examination with blood tests, special glycosylation studies, brain tests, and genetic testing. CDG guidelines stress that a full evaluation is important, because many CDG types can look similar.
Physical examination tests
-
General growth and nutrition check – The doctor measures weight, height, and head size and compares them with age charts. Poor growth, microcephaly, and signs of malnutrition can point toward a chronic metabolic or genetic disorder like CDG.
-
Neurologic tone and reflex exam – The doctor checks muscle tone, strength, and reflexes. Floppy tone, weak movements, and abnormal reflexes (too brisk or too weak) suggest a central nervous system disorder, which is common in COG8-CDG.
-
Cranial nerve and eye exam – Eye alignment, tracking, and facial movements are tested. Strabismus, abnormal eye movements, or weak facial muscles support a complex brain and nerve involvement typical of CDG.
-
Skin and joint examination – The doctor looks for dry skin, keratosis pilaris, joint contractures, or unusual postures. These findings match reports in COG8-CDG and show how glycosylation defects can affect skin and connective tissue.
-
Cardio-respiratory assessment – Heart sounds, breathing pattern, and oxygen levels are checked. While not specific, any heart or lung problems can change how safely other tests and treatments are planned in a child with CDG.
Manual and functional tests
-
Developmental milestone assessment – Simple tools and questions are used to see when the child sat, walked, and spoke. Very delayed milestones are typical in COG8-CDG and help show the severity of neurodevelopmental involvement.
-
Gross motor function tests – The doctor may ask older children to stand, walk, or reach, or may observe spontaneous movement in infants. Ataxia, unsteady gait, or inability to stand without support indicate brain and muscle problems related to CDG.
-
Fine motor and coordination tests – Tasks like grabbing toys, touching a finger to the nose, or stacking blocks can show poor coordination, tremor, or weakness, all common in neuro-metabolic disorders.
-
Feeding and swallow assessment – A speech-language or feeding specialist may watch the child eating or drinking. Signs such as choking, coughing, or long feeding times support the diagnosis of a central disorder that affects swallowing control.
Laboratory and pathological tests
-
Basic blood tests (CBC and chemistry) – A complete blood count and basic chemistry panel check for anemia, infection, kidney function, and electrolytes. These are not specific for COG8-CDG, but they are important to rule out other causes and to monitor general health.
-
Liver function and coagulation tests – Tests such as AST, ALT, GGT, albumin, and clotting times can show if the liver or clotting system is affected. Many CDG patients show low albumin or abnormal clotting due to under-glycosylated liver proteins.
-
Serum transferrin isoelectric focusing (IEF) – This is a key screening test for CDG. It separates transferrin forms by their electrical charge. In CDG type II disorders, including COG8-CDG, the pattern usually shows abnormal, under-sialylated transferrin.
-
Serum N-glycan analysis by mass spectrometry – This test looks in more detail at the sugar chains attached to serum proteins. In COG8-CDG, studies show specific defects in terminal sialylation of otherwise normal N-glycans.
-
O-glycan analysis in fibroblasts – In some patients, skin cells (fibroblasts) are grown and their O-glycosylation is studied. Disturbed O-glycans support a generalized Golgi glycosylation problem linked to COG8 deficiency.
-
Extended metabolic screening – Tests such as amino acids, organic acids, and lactate can help rule out other metabolic diseases. They may not be specific for CDG but are often part of a work-up for a child with unexplained hypotonia and developmental delay.
-
Molecular genetic testing of COG8 – This is the definitive test. Techniques such as Sanger sequencing or next-generation sequencing panels for CDG are used to look for pathogenic variants in both copies of COG8. Finding biallelic disease-causing variants confirms the diagnosis.
Electrodiagnostic tests
-
Electroencephalogram (EEG) – EEG records electrical activity in the brain. In children with COG8-CDG and seizures, EEG can show epileptic discharges or patterns such as generalized spikes, helping guide seizure treatment.
-
Nerve conduction studies and electromyography (EMG) – These tests measure how well nerves and muscles carry signals. In CDG they can be normal or show neuropathy or myopathy, helping doctors understand the extent of neuromuscular involvement.
Imaging tests
-
Brain MRI – MRI is very important in CDG. In many CDG types, including COG-related disorders, MRI may show brain atrophy, cerebellar changes, or delayed myelination, which match the child’s neurologic symptoms.
-
Cranial ultrasound (in infants) – In very young babies, ultrasound through the soft spot on the head can give an early view of brain structure before MRI is done. It may show enlarged spaces or other structural changes that need further study.
-
Abdominal ultrasound and other organ imaging – Ultrasound of the liver and spleen, or echocardiogram of the heart, can look for organ enlargement, structural problems, or other complications, which sometimes appear in CDG patients.
Non-pharmacological (non-drug) treatments
-
Comprehensive multidisciplinary care program
A structured care program brings together a metabolic specialist, neurologist, gastroenterologist, dietitian, physiotherapist, occupational therapist, speech therapist and social worker to follow the child regularly. The purpose is to monitor growth, nutrition, development, seizures, movement, vision, hearing and behaviour in one coordinated plan. The mechanism is not biochemical, but organisational: regular team reviews reduce missed problems, allow earlier treatment of complications and give families one central place for education and support. -
Individualised physiotherapy and stretching
Daily physiotherapy focuses on improving muscle tone, preventing joint contractures and maintaining posture in children with hypotonia or spasticity. The purpose is to keep muscles and joints flexible and prevent deformities that can worsen disability and pain. The mechanism is mechanical: repeated stretching, strengthening and positioning help preserve range of motion, support bone health and improve circulation, which together support mobility and comfort even when the underlying genetic defect cannot be changed. -
Occupational therapy for daily living skills
Occupational therapists train children and caregivers in safe ways to perform feeding, dressing, sitting, transferring and play activities using adapted tools and methods. The purpose is to maximise independence and reduce caregiver burden. Mechanistically, occupational therapy modifies the environment (chairs, cushions, splints, utensils) and tasks (breaking them into simple steps), allowing the child to use remaining motor skills more efficiently and preventing overuse injuries. -
Speech and language therapy, including communication aids
Many children with COG8-CDG have limited speech or oromotor control, so speech therapy works on safe swallowing, oral muscle coordination and language understanding. The purpose is to reduce choking risk and improve communication. The mechanism includes repetitive practising of sounds and swallowing patterns, plus alternative communication systems (picture boards, tablets, switches) that bypass weak muscles and allow the child to express needs and emotions. -
Feeding therapy and swallow safety strategies
Specialised feeding therapists assess for aspiration risk and teach techniques such as slow pacing, thickened feeds, upright positioning and chin-tuck posture during meals. The purpose is to prevent pneumonia and ensure adequate calorie and fluid intake. Mechanistically, changing food texture and positioning reduces the chance that food enters the airway and gives weak muscles more time to coordinate swallowing. -
Medical nutrition therapy with intolerance-aware diet
Dietitians design high-calorie, high-protein plans tailored to the child’s growth and food intolerances. In COG8-CDG, intolerance to wheat and dairy has been described, so careful restriction or elimination of these foods may improve gastrointestinal symptoms. The mechanism is straightforward: by removing triggers and ensuring enough calories, vitamins and minerals, nutrition therapy supports growth, immunity and energy, even though it cannot correct the glycosylation defect itself. -
Gastroesophageal reflux lifestyle measures
Before or alongside medicines, non-drug strategies like smaller frequent feeds, thickened feeds, keeping the child upright after meals, and raising the head of the bed can reduce reflux episodes. The purpose is to lessen pain, vomiting and aspiration risk. Mechanistically, these changes use gravity and slower gastric filling to keep stomach contents from flowing back into the oesophagus, which is especially valuable in neurologically impaired children. -
Orthotic devices, seating systems and standing frames
Custom ankle-foot orthoses, supportive seating systems and standing frames are used to improve posture, prevent foot deformities and encourage weight-bearing. The purpose is to protect bones and joints, reduce contractures and help the child participate in social and school activities. The mechanism is biomechanical: orthoses hold joints in functional alignment, redistribute pressure and allow more efficient movement with less fatigue. -
Respiratory physiotherapy and airway clearance
Children with severe hypotonia or scoliosis may have weak cough and poor lung expansion, so respiratory physiotherapy (percussion, vibration, assisted coughing, deep-breathing exercises) is used. The purpose is to reduce pneumonia risk and maintain lung function. Mechanistically, chest physiotherapy loosens mucus and helps move secretions from small airways to larger ones, where coughing or suctioning can remove them. -
Developmental and special education interventions
Early intervention programmes and special education teachers provide structured learning, sensory stimulation and behaviour support tailored to each child’s cognitive level. The purpose is to promote communication, learning and social engagement despite intellectual disability. Mechanistically, repeated, consistent teaching with visual, auditory and tactile cues helps the brain form alternative pathways and maintain existing skills longer. -
Psychological support and caregiver counselling
Families of children with COG8-CDG experience chronic stress, grief and practical burdens. Psychological support, support groups and social work services help them cope, plan respite care and access financial resources. The mechanism is psychosocial: by reducing caregiver burnout and teaching coping skills, the family is more able to provide stable care, which indirectly improves the child’s overall health and quality of life. -
Genetic counselling for family planning
Because COG8-CDG is autosomal recessive, each parent usually carries one non-working gene copy. Genetic counselling explains recurrence risk, carrier testing and prenatal or pre-implantation options. The purpose is informed decision-making and early diagnosis in future pregnancies. Mechanistically, this does not treat the child, but it reduces the chance of unexpected recurrence and allows earlier supportive care if another child is affected. -
Seizure-safety education and emergency plans
Families are trained on how to recognise seizures, protect the child from injury, use rescue medicines if prescribed, and when to call emergency services. The purpose is to reduce trauma, aspiration and delayed treatment. Mechanistically, preparedness shortens the time from seizure onset to intervention, which can reduce complications such as prolonged seizures or hypoxia. -
Non-drug pain and spasticity management (positioning, splints, heat, massage)
Soft tissue stretching, warm packs, gentle massage and careful repositioning are used to ease discomfort from spasticity, contractures or scoliosis. The purpose is to reduce pain without adding sedative medicines. Mechanistically, heat and massage improve blood flow and reduce muscle stiffness, while careful positioning limits pressure points and nerve compression. -
Sleep hygiene and environmental adjustments
Many neurologically disabled children have poor sleep. Consistent routines, limiting screen time, adjusting light and noise, and managing pain or reflux before bed are basic interventions. The purpose is to improve sleep quality for the child and caregivers. Mechanistically, predictable routines help reset circadian rhythms, while controlling discomfort reduces nighttime awakenings. -
Vaccination and infection-prevention practices
Standard childhood vaccines and, when appropriate, extra vaccines (like pneumococcal or influenza) are important because respiratory infections can be severe in child with neuromuscular weakness. The purpose is to prevent avoidable infections and hospitalisations. Mechanistically, vaccines prime the immune system to recognise and fight specific pathogens before they cause serious disease, while hand hygiene and avoiding sick contacts reduce exposure. -
Bone-health support with weight-bearing and sunlight
Limited mobility and anticonvulsant use can weaken bones. Weight-bearing through standing frames, physical activity as tolerated and safe sunlight exposure support bone mineralization. The purpose is to reduce fractures and deformities. Mechanistically, mechanical loading and vitamin D synthesis stimulate bone-forming cells, even when the underlying genetic defect persists. -
Assistive technology for mobility and access
Wheelchairs, walkers, adapted strollers and home modifications (ramps, bathroom aids) are used to improve safe mobility. The purpose is inclusion in family life, school and community despite severe motor impairment. Mechanistically, assistive devices substitute for weak muscles, reduce falls and allow the child to conserve energy for communication and learning. -
Palliative care and advanced care planning
For children with very severe disease, palliative care teams focus on comfort, symptom control and family goals, in parallel with active treatments. The purpose is to improve quality of life and support complex decisions about hospitalisations and interventions. Mechanistically, regular discussions align treatments with family values and avoid burdensome procedures that do not match expected benefits. -
Patient-organisation and peer-support engagement
Connecting with CDG-specific patient organisations and online communities provides practical tips, emotional support and research news. The purpose is empowerment and reduced isolation. Mechanistically, peer networks share lived experience, help families navigate health systems and may facilitate enrolment in natural-history studies or clinical trials when these become available.
Drug treatments
Important note: there is no FDA-approved drug that cures the underlying COG8 glycosylation defect. The medicines below are examples often used to control symptoms such as seizures, spasticity, reflux, constipation and nutritional problems in CDG and similar neuro-metabolic conditions. Doses and schedules must always be set by a specialist according to age, weight, organ function and other medicines.
-
Levetiracetam – antiepileptic for seizure control
Levetiracetam is a broad-spectrum antiepileptic drug used as adjunctive therapy for partial-onset, myoclonic and primary generalized tonic-clonic seizures. It is often chosen in CDG because it has relatively few drug interactions and can be given orally or intravenously. Usual practice is to start at a low twice-daily dose and increase slowly while monitoring behaviour, mood and kidney function. Side effects can include irritability, sleepiness and behavioural changes. -
Valproate (valproic acid / valproate sodium) – antiepileptic for difficult seizures
Valproate is a powerful antiepileptic medicine used for many seizure types, including generalized seizures. In carefully selected patients, it can help when seizures are not controlled by other drugs. It is usually given two or three times daily, with close monitoring of liver function, platelet counts and drug levels. Important side effects include liver toxicity, pancreatitis, weight gain, tremor and a high risk of birth defects in pregnancy, so its use in children, especially girls, must be weighed very carefully. -
Topiramate – adjunctive antiepileptic
Topiramate is another broad-spectrum antiepileptic that can be used as mono- or add-on therapy for partial and generalized seizures. Clinicians often start with a very low once-daily dose and increase weekly to minimise cognitive slowing, appetite loss and kidney-stone risk. In CDG, it may be added when seizures remain frequent despite first-line drugs. It can also help with certain headache patterns in older patients, but monitoring for weight loss, metabolic acidosis and eye problems is important. -
Clonazepam – benzodiazepine for myoclonic or resistant seizures
Clonazepam is a benzodiazepine used for myoclonic and some focal seizures, usually as an add-on when other antiepileptics are insufficient. It is started at a small bedtime dose and adjusted gradually. Its mechanism is to enhance GABAergic inhibition in the brain, which calms overactive neurons. Common side effects are drowsiness, drooling, poor coordination and dependence with long-term use, so doctors usually review the need for continued therapy regularly. -
Diazepam – rescue or spasticity medicine
Diazepam can be used in emergency situations for prolonged seizures or severe spasms, and sometimes in low doses at night for muscle stiffness. It acts quickly by enhancing GABA activity, but it also causes sedation and respiratory depression if overused. In practice, families may be given a rescue form (oral, rectal or nasal) with clear instructions for when to administer it and when to call an ambulance, while daily use is kept as low as possible to avoid tolerance and dependence. -
Baclofen – oral or intrathecal antispasticity agent
Baclofen is a GABA-B receptor agonist used to reduce spasticity and muscle rigidity, usually in children with significant motor impairment. It can be given orally several times per day or, in very severe cases, via an implanted intrathecal pump. The purpose is to ease stiffness, improve comfort and make physiotherapy and care easier. Side effects include sleepiness, low muscle tone, dizziness and, with pumps, serious withdrawal if delivery is suddenly interrupted, so dose changes must always be slow and supervised. -
Tizanidine – additional oral antispasticity drug
Tizanidine is a short-acting alpha-2 adrenergic agonist approved for muscle spasticity that may be used when baclofen alone is not sufficient or causes too many side effects. It is usually given several times daily with gradual dose adjustments. It reduces muscle tone by decreasing excitatory signals in the spinal cord. Side effects can include low blood pressure, dry mouth, sedation and liver enzyme elevations, so liver tests and blood pressure checks are recommended. -
Omeprazole – proton pump inhibitor for severe reflux
Omeprazole is a proton pump inhibitor that strongly reduces stomach acid production and is widely used to treat gastroesophageal reflux disease (GERD), including in infants and children with neurologic impairment. It is typically given once daily before a meal. In COG8-CDG, it can protect the oesophagus from acid damage and lessen pain and vomiting. Possible side effects include diarrhoea, headache and, with long-term use, altered mineral and vitamin absorption, so regular review is needed. -
Ondansetron – anti-nausea medicine
Ondansetron is a 5-HT3 receptor antagonist used to treat nausea and vomiting, originally for chemotherapy and post-operative settings but also useful in severe gastrointestinal illnesses. Short courses may help children with CDG who have repeated vomiting due to infections or reflux. It is usually given as an oral solution or tablet several times daily for a few days. Side effects can include constipation and, rarely, heart-rhythm changes, so doctors avoid combining it with other QT-prolonging drugs. -
Polyethylene glycol 3350 – osmotic laxative for constipation
Chronic constipation is common in neurologically impaired children. Polyethylene glycol 3350 powder is an osmotic laxative that increases water in the stool, making it softer and easier to pass. It is mixed with liquid once daily, with doses adjusted to produce one or two soft stools per day. Side effects can include bloating, gas and, rarely, electrolyte imbalance if overused, so medical supervision is needed in medically complex children. -
Metoclopramide – pro-kinetic for selected reflux or gastroparesis cases
Metoclopramide increases stomach and upper intestinal motility and can help relieve nausea and reflux when standard measures fail. Because long-term use carries a serious risk of tardive dyskinesia and other movement disorders, guidelines limit its duration and reserve it for refractory cases. In children with CDG, it may be used for short periods at the lowest effective dose, with close monitoring for abnormal movements or mood changes. -
Cyproheptadine – appetite stimulant in selected children
Some clinicians use cyproheptadine, an antihistamine with serotonin-antagonist properties, off-label to stimulate appetite and weight gain in children with severe failure to thrive. It is given orally in low divided doses, often at bedtime because of sedation. Side effects include drowsiness, dry mouth, constipation and, in rare cases, paradoxical excitement. Because of its anticholinergic and sedative effects, careful monitoring and specialist guidance are important. -
Parenteral multivitamin preparations (e.g., paediatric multivitamin injections)
For children on long-term parenteral nutrition or with severe malabsorption, injectable multivitamin products can prevent deficiencies of fat- and water-soluble vitamins. They are added to intravenous nutrition solutions according to age-based dosing guidelines. Side effects may include allergic reactions or imbalances if dosing is inappropriate, so they are used within a structured nutrition plan. -
Vitamin D supplementation (oral)
Vitamin D drops or tablets are often prescribed to support bone health in children with limited mobility or anticonvulsant use, which can both reduce bone mineral density. Typical practice is daily or weekly dosing adjusted to maintain blood vitamin D in the target range. Side effects are rare at recommended doses but can include high calcium levels if accidentally overdosed, so blood tests are sometimes used for monitoring. -
Iron supplementation for iron-deficiency anaemia
If blood tests show iron-deficiency anaemia due to poor intake or chronic illness, oral iron drops or syrups may be used. Doses are weight-based and given once or twice daily, often with vitamin C-rich juice to improve absorption. Side effects can include stomach upset and constipation, so diet and laxatives may need adjustment. Treating anaemia improves energy, oxygen delivery and overall resilience in medically fragile children. -
Proton-pump inhibitors or H2 blockers other than omeprazole (e.g., other standard formulations)
Depending on local availability and individual response, other acid-suppressing medicines may be used if omeprazole is not tolerated. They are prescribed with similar goals—to reduce oesophageal damage and pain—but require monitoring for long-term side effects such as nutrient malabsorption and infections. Choice between agents depends on age, drug interactions and clinician experience. -
Short-course antibiotics for proven infections
Children with COG8-CDG are not automatically immunodeficient, but feeding difficulties, reflux and immobility may increase infection risk. When bacterial infections such as pneumonia or urinary infections are confirmed, standard antibiotics are used according to guidelines. The mechanism is pathogen-specific killing or growth inhibition, and the goal is rapid infection control to avoid sepsis or prolonged hospitalisation. Overuse is avoided to limit resistance and side effects. -
Antipyretic and analgesic medicines (paracetamol, ibuprofen if appropriate)
Standard pain and fever medicines can help manage discomfort from infections, procedures or musculoskeletal problems. Doses are strictly weight-based, and contraindications (such as kidney disease or bleeding risk for ibuprofen) are checked. The purpose is to improve comfort, sleep and participation in therapy sessions. Mechanistically, they block prostaglandin pathways that mediate pain and fever. -
Rescue bronchodilators in children with reactive airways
If a child with COG8-CDG also has asthma-like symptoms or recurrent wheezing, inhaled bronchodilators may be used to open the airways during attacks. Delivery through spacers or nebulisers is adapted to the child’s abilities. The mechanism is relaxation of airway smooth muscle, improving airflow and oxygenation. These drugs are not specific to CDG, but they can be important in overall respiratory management. -
Nutritional formulas and enteral feeds (technically foods but prescribed like drugs)
Specialised high-calorie or elemental formulas, sometimes free from specific proteins like cow’s-milk protein or gluten, can be prescribed when oral feeding is insufficient. They may be delivered through nasogastric or gastrostomy tubes. The purpose is to secure consistent nutrition and medication delivery. Side effects include diarrhoea, bloating or tube complications, so formulas are adjusted under dietitian and physician supervision.
Dietary molecular supplements
(Evidence for specific supplements in COG8-CDG is extremely limited, so the options below are general nutritional supports sometimes considered in CDG or complex neurological disorders. They should only be used under specialist supervision to avoid imbalance or interactions.)
-
Multivitamin and mineral supplement – used to cover small daily requirements of vitamins and trace elements that may be missing from restricted or poor oral intake diets, supporting immune function, energy production and bone health.
-
Vitamin D drops – provide a controlled daily dose to maintain normal vitamin D levels when sunlight exposure or diet is low, promoting calcium absorption and bone mineralisation in children with limited mobility.
-
Calcium supplementation – used if dietary calcium is low due to dairy intolerance, helping preserve bone strength; given in divided doses, often alongside vitamin D, with monitoring to avoid excess levels.
-
Omega-3 fatty acids (fish-oil based) – may be added to support brain and retinal membrane structure and possibly reduce inflammation, although solid evidence in COG8-CDG is lacking; doses are adjusted to body weight and tolerance.
-
Carnitine supplementation – sometimes used in metabolic disorders when carnitine levels are low, with the aim of supporting fatty-acid oxidation and energy production, but levels and benefits must be checked by metabolic specialists before and during use.
-
Coenzyme Q10 (ubiquinone) – occasionally tried in mitochondrial or energy-metabolism disorders to support electron-transport chain activity; in CDG, evidence is minimal, so its use is experimental and monitored for gastrointestinal side effects.
-
B-complex vitamins (including B1, B6, B12, folate) – ensure adequate cofactors for many enzymatic reactions and may correct specific deficiencies contributing to anaemia or neuropathy, but routine high-dose use without documented deficiency is not recommended.
-
Trace elements (zinc, selenium, copper in balanced formulations) – sometimes needed in children on long-term enteral or parenteral nutrition to support immune function, antioxidant systems and growth; dosing must be guided by laboratory monitoring to prevent toxicity.
-
Probiotic preparations – may be tried to improve gut microbiota balance and reduce diarrhoea or constipation in some children, although high-quality data in CDG are lacking; only medically reviewed products should be used in immunologically fragile patients.
-
Medium-chain triglyceride (MCT) oil – can be added to feeds to provide energy that is more easily absorbed and metabolised than long-chain fats, useful when weight gain is poor; dose must be increased slowly to avoid diarrhoea or cramps.
Immunity-booster / regenerative / stem-cell-related approaches
There are no proven stem-cell or gene-therapy drugs specifically approved for COG8-CDG as of early 2026. Research in CDG is exploring targeted therapies, but these are mostly experimental and limited to other subtypes. The points below explain general concepts that may be discussed in specialist centres, not established routine treatments.
-
Optimised vaccination and infection-prevention plan – while not a “drug booster,” a complete vaccination schedule and influenza / pneumococcal vaccines, plus early treatment of infections, are the most evidence-based ways to support immune defence in children with complex chronic disease.
-
Immunoglobulin replacement (IVIG or SCIG) in documented antibody deficiency – in rare CDG subtypes with proven antibody deficiency, clinicians may use immunoglobulin therapy to reduce serious infections; this is not automatically needed in COG8-CDG and requires formal immunology assessment.
-
Experimental substrate or cofactor supplementation – in some CDG types, monosaccharides such as mannose or galactose can partially bypass certain enzymatic blocks, but such targeted therapy has not been demonstrated for COG8-CDG and should only be considered in research protocols after genetic confirmation that it is appropriate.
-
Gene-therapy and RNA-based approaches (research stage) – preclinical research in CDG is studying viral vectors, antisense oligonucleotides and other methods to correct or compensate for defective glycosylation genes. For COG8-CDG, this remains theoretical, but families may hear about such projects; participation would only occur in tightly regulated clinical trials.
-
Hematopoietic stem-cell or organ transplantation (very rare, subtype-specific) – in a few other metabolic disorders, bone-marrow or liver transplantation can improve enzyme activity. For COG8-CDG there is no evidence that such transplants correct the Golgi trafficking defect, so they are not standard care and would only be considered in exceptional situations for specific organ failure, not for the CDG itself.
-
Structured physical rehabilitation as “functional regeneration” – intensive physical, occupational and speech therapy cannot regrow damaged neurons but can promote neuroplasticity, allowing remaining circuits to compensate. In practice, this is currently the most realistic form of “regenerative” care available for COG8-CDG.
Surgeries (supportive, not curative)
-
Gastrostomy tube (G-tube) placement
For children who cannot safely maintain nutrition by mouth because of severe swallowing difficulty, a surgeon can place a feeding tube directly into the stomach. The purpose is to secure long-term, safe delivery of calories, fluids and medicines while reducing aspiration risk. This procedure does not treat the genetic cause but can dramatically improve growth and reduce hospital admissions for dehydration and pneumonia. -
Fundoplication for severe reflux
In selected children with life-threatening reflux that does not respond to medical and positioning therapy, a fundoplication may be offered. The surgeon wraps the upper part of the stomach around the lower oesophagus to strengthen the valve and reduce acid reflux. The aim is to prevent chronic aspiration, oesophagitis and pain. Risks include gas bloat, difficulty vomiting and surgical complications, so the decision is made carefully by a multidisciplinary team. -
Orthopaedic tendon-lengthening or contracture-release surgery
If spasticity and contractures cause fixed deformities that interfere with sitting, standing or hygiene, orthopaedic surgeons may lengthen tendons or release tight soft tissues. The purpose is to improve positioning, ease care and sometimes enable use of standing frames or walkers. These surgeries work by mechanically changing muscle-tendon length and joint alignment but require intensive post-operative physiotherapy to maintain benefits. -
Spinal surgery for severe scoliosis
Progressive scoliosis can compress lungs and make sitting painful. In severe cases, spinal fusion or growth-friendly instrumentation may be considered to stabilise the spine. The goal is to preserve lung capacity, reduce pain and improve sitting balance. Because these are major operations with significant risk in medically fragile children, detailed risk–benefit discussions and pre-operative optimisation are essential. -
Tracheostomy for chronic airway protection (rare, individualised)
If a child has repeated life-threatening respiratory events due to poor airway protection or chronic ventilation needs, tracheostomy may be considered. This procedure creates a direct airway in the neck to allow more secure breathing support and suctioning. It does not change the underlying CDG but can make intensive respiratory care safer and more manageable at home with appropriate training.
Prevention strategies
Because COG8-CDG is a genetic disease, we cannot yet prevent its occurrence, but we can reduce complications:
-
Early diagnosis through awareness of CDG in infants with failure to thrive, developmental delay and abnormal transferrin glycoforms.
-
Regular follow-up with a multidisciplinary CDG-experienced team to catch seizures, scoliosis, nutritional decline and organ problems early.
-
Full vaccination schedule plus flu and pneumococcal vaccines according to national guidelines to prevent severe infections.
-
Prompt treatment of minor illnesses and careful hydration during fevers or vomiting to avoid hospitalisation and metabolic decompensation.
-
Early institution of physiotherapy and orthotics to prevent fixed contractures and secondary deformities.
-
Routine screening for vision, hearing and scoliosis so supportive measures can start before disability worsens.
-
Nutrition monitoring with growth charts and lab tests to prevent severe malnutrition, micronutrient deficiencies and obesity.
-
Dental hygiene and regular dental care to prevent caries and infection in children with feeding difficulties and reflux.
-
Genetic counselling for parents and extended family to prevent unexpected recurrence in future pregnancies through carrier testing and prenatal options.
-
Psychological support and respite care to prevent caregiver burnout, which can indirectly affect the child’s safety and consistency of care.
When to see doctors (or emergency care)
Families should maintain regular planned visits with their metabolic / neurology / paediatrics team, usually every few months, but there are also urgent situations where medical review is needed immediately. Seek emergency care if the child has prolonged or repeated seizures, sudden breathing difficulty, blue lips, severe vomiting or diarrhoea with poor urine output, unusual sleepiness, high fever not responding to antipyretics, or sudden loss of previously acquired abilities. See the doctor promptly for feeding refusal, new or worsening reflux, constipation lasting several days despite treatment, new contractures, rapid scoliosis progression, unexplained pain, or any marked change in tone or behaviour. Regular appointments are also important for medication review, blood tests and adjusting therapy plans as the child grows.
What to eat and what to avoid
Because published cases mention intolerance to wheat and dairy in COG8-CDG, diet should be planned carefully with a metabolic dietitian:
-
Eat: energy-dense foods that the child tolerates, such as well-tolerated grains (e.g., rice), tubers, fruits, vegetables, and safe protein sources (meat, fish, eggs or plant protein as tolerated).
-
Eat: small, frequent meals or continuous feeds rather than large meals to reduce reflux and vomiting.
-
Eat: vitamin- and mineral-rich foods, using fortified formulas when needed to cover micronutrient needs.
-
Eat: enough fluid, provided orally or via tube, to prevent dehydration, especially during illness or hot weather.
-
Avoid or limit: foods that have clearly triggered symptoms in the individual child, which may include wheat-containing products or cow’s-milk dairy if intolerance has been documented.
-
Avoid: very hard, dry or sticky textures (nuts, tough meats, chewy candies) in children at risk of choking; use softer, pureed or thickened textures as recommended by the feeding team.
-
Avoid: sugary drinks and junk foods that add calories without nutrients and can worsen reflux and dental caries.
-
Avoid: drastic unproven “metabolic” or “detox” diets found online without discussing them with the metabolic team, because they may cause malnutrition.
-
Use with caution: high-fat diets or ketogenic diets, which are sometimes used for epilepsy but may not be appropriate in CDG without specialist supervision.
-
Review regularly: dietary plan and growth charts at clinic visits, adjusting energy, protein, fluid and micronutrient intake as the child grows and as tolerance changes.
Frequently asked questions (FAQs)
-
Is carbohydrate-deficient glycoprotein syndrome type IIh the same as general CDG?
COG8-CDG is one specific subtype within the larger group of congenital disorders of glycosylation. All CDGs involve problems attaching sugar chains to proteins or lipids, but each subtype has a different defective gene and can have different symptoms and severity. COG8-CDG specifically affects the COG8 subunit of the Golgi trafficking complex. -
What are the main symptoms of COG8-CDG?
Reported patients typically have severe developmental delay or intellectual disability, low or abnormal muscle tone, feeding difficulties, failure to thrive, seizures and intolerance to wheat and dairy products. Many also have abnormal blood glycoprotein patterns and may show brain MRI changes or other organ involvement, although details vary between individuals. -
How is COG8-CDG diagnosed?
Evaluation usually starts with clinical suspicion based on symptoms and a blood test called transferrin isoform analysis, which can show a CDG-type pattern. If this suggests a CDG, next-generation sequencing panels or exome sequencing are used to identify a pathogenic COG8 mutation. Diagnosis may be confirmed by additional biochemical or cell-based tests in specialised laboratories. -
Is there a cure for COG8-CDG?
At present, there is no cure that directly corrects the COG8 defect or fully normalises glycosylation. All available treatments are supportive and aim to improve symptoms, prevent complications and optimise quality of life. Research in CDG is active and exploring gene- and substrate-based therapies, but none is yet established for this subtype. -
Can diet alone treat this disease?
Dietary management is very important because many children have feeding intolerance, reflux and possible wheat or dairy sensitivity, but diet cannot fix the underlying Golgi transport defect. Instead, nutrition therapy aims to secure enough calories, protein and micronutrients to support growth and immunity and to reduce gastrointestinal symptoms as much as possible. -
Will my child always have seizures?
Epilepsy is common in CDG but not universal, and seizure patterns differ between children. With modern antiepileptic drugs and careful monitoring, many families achieve reasonable seizure control, although medication side effects and breakthrough seizures may still occur. Treatment choice depends on seizure type, EEG findings and overall health. -
What is the life expectancy in COG8-CDG?
Because only a very small number of patients have been reported, long-term survival data are limited. Some children with severe forms of CDG die in childhood due to infections, organ failure or seizures, while others survive longer with intensive supportive care. Prognosis depends on the severity of organ involvement and access to comprehensive management rather than genetics alone. -
Can my other children be affected?
COG8-CDG is autosomal recessive, which means both parents usually carry one non-working COG8 gene copy. With each pregnancy, there is a 25% chance that the baby will be affected, a 50% chance of being a carrier and a 25% chance of inheriting two working copies. Genetic counselling helps families understand these numbers and discuss carrier testing and prenatal or pre-implantation diagnosis. -
Will my child walk or talk?
Published cases suggest that many children with COG8-CDG have profound psychomotor delay, which means walking and speech may be very limited or absent. However, with early and intensive physiotherapy, occupational therapy and communication support, some children may achieve partial milestones or use alternative communication systems to express themselves. -
Is pregnancy safe for carriers?
Carriers (parents) are usually healthy and can have normal pregnancies, but if the fetus inherits two non-working COG8 copies, they will be affected. For mothers who are carriers but not affected, pregnancy management follows usual obstetric care, with the main special consideration being genetic counselling and prenatal testing options rather than maternal medical complications. -
Can my child attend school?
Most children with COG8-CDG will require special education and one-to-one support, but participation in school or early-intervention programmes is usually beneficial. Special education teams adapt teaching methods, communication tools and the physical classroom environment to the child’s needs, promoting social interaction and sensory stimulation. -
What follow-up tests are needed over time?
Depending on the child’s presentation, follow-up may include regular growth measurements, liver and kidney function tests, blood counts, coagulation studies, nutritional labs, brain imaging, EEGs, echocardiograms, and spine and hip X-rays. The exact schedule is individualised, but the goal is to detect treatable complications before they cause irreversible harm. -
Are there clinical trials for COG8-CDG?
Because COG8-CDG is extremely rare, most trials recruit broader CDG populations or focus on more common subtypes. Families interested in research can register with CDG patient organisations, rare-disease networks or research registries, which may notify them if relevant studies arise. Participation is always voluntary and should be discussed with the care team. -
How can families cope emotionally with this diagnosis?
Living with COG8-CDG is emotionally demanding. Psychological counselling, social-worker support, spiritual care where desired, and connection with other CDG families can greatly reduce isolation and stress. Many families find it helpful to build a network of extended family, friends and respite services so that caregivers can rest and stay healthy themselves. -
What is the most important message for caregivers?
The most important message is that, although there is no curative therapy yet, good supportive management can make a real difference in comfort, development and family quality of life. Working closely with a multidisciplinary team, watching for early signs of complications, and advocating for your child’s needs in health, education and social systems are key steps that caregivers can take.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: February 03, 2025.
